Journal of Clinical Endocrinology & Metabolism, Vol 80, 2806-2814, Copyright © 1995 by Endocrine Society

ARTICLES

Somatostatin receptors in human prostate and prostate cancer

JC Reubi, B Waser, JC Schaer and R Markwalder
Division of Cell Biology and Experimental Cancer Research, University of Berne, Switzerland.

Benign as well as malignant human prostatic tissues were evaluated for their content of somatostatin (SRIH) receptors (SRIH-R). In vitro receptor autoradiography techniques on cryostat sections were performed using 125I-labeled [Tyr3]octreotide as well as 125I-labeled [Leu8,D- Trp22,Tyr25]SRIH-28 as radioligands. SRIH-R were identified in all normal and hyperplastic prostates in the smooth muscles of the stroma, whereas the glands did not express the receptors. Muscular nodules were strongly receptor positive as well. The receptors were of high affinity (Kd = 0.4 nmol/L) and high specificity for biologically active SRIH analogs; high affinity for SRIH-14, SRIH-28, and octreotide was detected, suggesting the presence of the SSTR2 receptor subtype. In situ hybridization studies confirmed the presence of SSTR2 messenger ribonucleic acid in these tissues. Primary prostate cancers did not have SRIH-R identified with 125I-labeled [Tyr3]octreotide. However, they were expressing SRIH-R identified with 125I-labeled [Leu8,D- Trp22,Tyr25]SRIH-28, with a high affinity for SRIH-14 and SRIH-28, but low affinity for octreotide. The receptors were located on tumoral cells. In situ hybridization studies revealed a preferential expression of SSTR1. Primary human prostate cancers, therefore, express a different SRIH-R subtype than benign prostate tissue. Several veins and the ganglion cells from the prostatic plexus in the surroundings of the tumors were expressing SRIH-R with high affinity for octreotide as well. These data suggest that the human prostate as well as prostate cancers may be targets for SRIH therapy; however, SRIH analogs with different selectivities for SRIH-R subtypes are required in each case.

This article has been cited by other articles:

				J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF]

				L. J. Hofland and S. W. J. Lamberts The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance Endocr. Rev., February 1, 2003; 24(1): 28 - 47. [Abstract] [Full Text] [PDF]

				P. D. Zapata, R. M. Ropero, A. M. Valencia, L. Buscail, J. I. Lopez, R. M. Martin-Orozco, J. C. Prieto, J. Angulo, C. Susini, P. Lopez-Ruiz, et al. Autocrine Regulation of Human Prostate Carcinoma Cell Proliferation by Somatostatin through the Modulation of the SH2 Domain Containing Protein Tyrosine Phosphatase (SHP)-1 J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 915 - 926. [Abstract] [Full Text] [PDF]

				A. Colao, P. Marzullo, S. Spiezia, A. Giaccio, D. Ferone, G. Cerbone, A. Di Sarno, and G. Lombardi Effect of Two Years of Growth Hormone and Insulin-Like Growth Factor-I Suppression on Prostate Diseases in Acromegalic Patients J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3754 - 3761. [Abstract] [Full Text]

				G. Halmos, A. V. Schally, B. Sun, R. Davis, D. G. Bostwick, and A. Plonowski High Expression of Somatostatin Receptors and Messenger Ribonucleic Acid for Its Receptor Subtypes in Organ-Confined and Locally Advanced Human Prostate Cancers J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2564 - 2571. [Abstract] [Full Text]

				J. C. Reubi, J. A. Laissue, B. Waser, D. L. Steffen, R. W. Hipkin, and A. Schonbrunn Immunohistochemical Detection of Somatostatin sst2a Receptors in the Lymphatic, Smooth Muscular, and Peripheral Nervous Systems of the Human Gastrointestinal Tract: Facts and Artifacts J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2942 - 2950. [Abstract] [Full Text]

				A. Plonowski, A. V. Schally, A. Nagy, B. Sun, and K. Szepeshazi Inhibition of PC-3 Human Androgen-independent Prostate Cancer and Its Metastases by Cytotoxic Somatostatin Analogue AN-238 Cancer Res., April 1, 1999; 59(8): 1947 - 1953. [Abstract] [Full Text] [PDF]

				R. Markwalder and J. C. Reubi Gastrin-releasing Peptide Receptors in the Human Prostate: Relation to Neoplastic Transformation Cancer Res., March 1, 1999; 59(5): 1152 - 1159. [Abstract] [Full Text] [PDF]

				N. Lamharzi, A. V. Schally, M. Koppan, and K. Groot Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors PNAS, July 21, 1998; 95(15): 8864 - 8868. [Abstract] [Full Text] [PDF]

				A. Colao, P. Marzullo, D. Ferone, S. Spiezia, G. Cerbone, V. Marinò, A. Di Sarno, B. Merola, and G. Lombardi Prostatic Hyperplasia: An Unknown Feature of Acromegaly J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 775 - 779. [Abstract] [Full Text]

				A. Nagy, A. V. Schally, G. Halmos, P. Armatis, R.-Z. Cai, V. Csernus, M. Kovacs, M. Koppan, K. Szepeshazi, and Z. Kahan Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin PNAS, February 17, 1998; 95(4): 1794 - 1799. [Abstract] [Full Text] [PDF]

				A. A. Sinisi, A. Bellastella, D. Prezioso, M. R. Nicchio, T. Lotti, M. Salvatore, and D. Pasquali Different Expression Patterns of Somatostatin Receptor Subtypes in Cultured Epithelial Cells from Human Normal Prostate and Prostate Cancer J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2566 - 2569. [Abstract] [Full Text] [PDF]

				Q. Liu and A. Schonbrunn Agonist-induced Phosphorylation of Somatostatin Receptor Subtype 1 (Sst1). RELATIONSHIP TO DESENSITIZATION AND INTERNALIZATION J. Biol. Chem., January 26, 2001; 276(5): 3709 - 3717. [Abstract] [Full Text] [PDF]